Clinical Analysis: Tonsillitis-like Symptoms on Eating + Continuous Headache (Worse on Bending) + No Fever

Most Likely Diagnosis: Chronic/Subacute Rhinosinusitis with Postnasal Drip

• Throat irritation, rawness, and soreness that is especially noticeable when swallowing during eating
• A "cobblestone" appearance of the posterior pharyngeal wall on examination (lymphoid follicle hypertrophy from chronic irritation)
• Throat clearing, bad breath (from infected mucus), and a "globus" sensation
• The tonsils may appear mildly inflamed/reactive, mimicking tonsillitis

• Frontal sinusitis - pain over the forehead
• Maxillary sinusitis - pain over cheeks, upper teeth, and jaw
• Ethmoid sinusitis - pain behind and between the eyes
• Sphenoid sinusitis - pain at the vertex or behind the eyes (often described as a "deep" headache)

• Chronic rather than acute bacterial sinusitis (chronic sinusitis rarely causes fever)
• Could also represent non-infectious rhinosinusitis (allergic, vasomotor, or irritant-driven)
• Alternatively, a viral rhinosinusitis (the common cold progressing to sinusitis), where fever is often absent or low-grade

Differential Diagnoses to Consider

Key Clinical Points

• Periorbital swelling or redness (orbital cellulitis)
• High fever with severe headache (intracranial spread)
• Visual changes, diplopia
• Stiff neck, photophobia (meningitis)
• Altered consciousness

Suggested Workup

1. Clinical exam - Anterior rhinoscopy/nasal endoscopy; examine posterior pharynx for cobblestoning and purulent postnasal drip; percuss/press over sinuses for tenderness
2. CT sinuses (non-contrast) - Gold standard for sinusitis diagnosis; reveals mucosal thickening, air-fluid levels, ostiomeatal complex obstruction
3. Nasal endoscopy - Direct visualization (ENT referral if available)
4. Allergy testing - If history suggests allergic triggers
5. Dental X-rays/OPG - If maxillary sinus involved and unilateral, to rule out odontogenic cause

Initial Management

• Saline nasal irrigation (e.g., neti pot, saline sprays) - first-line for symptom relief
• Intranasal corticosteroids (e.g., mometasone, budesonide spray) - reduce mucosal inflammation
• Decongestants (e.g., oxymetazoline short-term, or oral pseudoephedrine) - help sinus drainage
• Antihistamines - if allergic component suspected
• Antibiotics (amoxicillin-clavulanate) - ONLY if acute bacterial sinusitis confirmed (symptoms >10 days without improvement); not first-line for chronic cases
• Treat the throat irritation with warm saline gargles, honey - this will improve as postnasal drip is treated

Chronic Rhinosinusitis (CRS): Latest Clinical Guidelines 2024-2025

Guideline Sources

Part 1: Diagnosis - New 2025 Standards

Strong Recommendations (must follow)

• Distinguish ABRS from viral/noninfectious rhinosinusitis. ABRS requires either:
  • Symptoms (purulent discharge + nasal obstruction/facial pressure) persisting >10 days without improvement, OR
  • "Double worsening" - symptoms that improve then worsen again within 10 days
• Objectively confirm CRS before labeling it as such - this requires anterior rhinoscopy, nasal endoscopy, OR CT scan showing sinonasal inflammation. Clinical history alone is insufficient.

Key Diagnostic Principle (New in 2025)

• Asthma
• Aspirin-exacerbated respiratory disease (AERD) - new addition in 2025
• Cystic fibrosis
• Primary ciliary dyskinesia
• Immunocompromise

Part 2: Medical Management of CRS

2025 First-Line Treatment (Recommendations)

1. Saline nasal irrigation - first-line, recommended for all CRS patients
2. Topical intranasal corticosteroids (INCS) - recommended for symptom relief (e.g., mometasone, fluticasone, budesonide)
3. Both can be used together

What NOT to Do (2025 Guideline Prohibitions)

Antibiotics - ABRS (Updated 2025)

• Watchful waiting without antibiotics is now recommended for ALL patients with uncomplicated ABRS (previously only "mild" cases) - key change from 2015
• If antibiotics chosen: amoxicillin WITH OR WITHOUT clavulanate for 5-7 days (changed from amoxicillin alone)
• Reassess after 3-5 days if no improvement; switch antibiotic if ABRS confirmed

Part 3: Biologics for CRS with Nasal Polyps (CRSwNP) - 2025 Updates

Approved Biologics (Type 2 inflammation / severe uncontrolled CRSwNP)

Key 2025 Evidence: EVEREST Trial (Lancet Respir Med, 2025)

• Dupilumab was significantly superior for all primary and secondary endpoints at 24 weeks
• Nasal polyp score reduction: dupilumab better by -1.60 points (p<0.0001)
• Smell improvement (UPSIT): dupilumab better by +8.0 points (p<0.0001)
• Safety was comparable between both agents

Meta-Analysis: Real-World Biologic Data (Allergy, 2025)

• All four biologics show strong efficacy and good safety in real-world settings
• Real-world outcomes were superior to phase 3 RCT results
• Dupilumab showed the most notable effects on polyp score and SNOT-22
• All biologics had low discontinuation rates due to adverse events

Guideline Position on Biologics (AAO-HNS 2025):

• Recommend educating CRSwNP patients about biologics as an option
• Recommend against routine biologic use in CRS without polyps
• Biologics are positioned as adjunct/alternative to surgery for severe uncontrolled CRSwNP

Part 4: Surgical Management - New 2025 CPG (Shin et al.)

Strong Recommendations

1. Verify CRS diagnosis before surgery - confirm established diagnostic criteria (not just imaging alone)
2. Assess surgical candidacy based on: symptoms, disease characteristics, quality of life, and prior medical/surgical therapy
3. Do NOT prescribe antibiotics preoperatively if significant/persistent purulent nasal discharge is absent on examination

Key Recommendations

• Do NOT require a predefined fixed course of medical therapy as a prerequisite to surgery - individualize this
• CT scan with fine-cut protocol should be obtained before all sinus surgery for planning
• Do NOT determine the extent of surgery solely based on arbitrary thresholds of mucosal thickening or opacification on CT
• For CRS with polyps, osteitis, bony erosion, or fungal disease: surgery must include full sinus cavity exposure and diseased tissue removal - balloon dilation alone is insufficient
• Counsel patients preoperatively: CRS is a chronic disease; surgery manages it but does not cure it; long-term medical management will still be required

Patient Selection: Who Benefits Most from Surgery?

• CRS with nasal polyps (CRSwNP)
• Polyps with bony erosion
• Eosinophilic mucin
• Fungal balls (mycetoma)
• Patients failing maximal medical therapy

Summary: 2025 CRS Management Algorithm

CRS confirmed (objective: endoscopy or CT)
        |
        ├── CRS without polyps (CRSsNP)
        │     ├── Saline irrigation + INCS → 12 weeks
        │     ├── No antifungals, no routine antibiotics, no biologics
        │     └── Failure → Consider surgery (ESS)
        │
        └── CRS with polyps (CRSwNP)
              ├── Saline irrigation + INCS → assess
              ├── Assess for Type 2 comorbidities (asthma, AERD, eosinophilia)
              ├── Severe uncontrolled → Biologics (dupilumab preferred)
              └── Surgical candidate → ESS with full sinus opening
                    └── Post-op: continued medical management long-term